Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — INVO Bioscience — Investor Presentation (July 2023)
26 slides from Invo Fertility's investor presentation, Jul 24, 2023
Slide 1: INVO Bioscience Corporate Investor Presentation
© INVO INVO Bioscience Nasdaq: INVO Corporate Investor Presentation July 2023 Fertility Within Reach Making advanced fertility care more accessible and inclusive
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation (this “Presentation”) has been prepared by INVO Bioscience Inc. (the "Company") solely for informational purposes. This Presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any of our secu
Slide 3: Forward-Looking Statements
Forward-Looking Statements This Presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this Presentation that are not of a historical natu
Slide 4: Focused on Democratizing the Fertility Market
Focused on Democratizing the Fertility Market Unique Product/Procedure Novel INVOcell-enabled IVC procedure provides an | alternative advanced fertility treatment that reduces the | need for lab equipment and resources and has shown comparable success to traditional IVF at a lower cost Innovative Co
Slide 5: INVOcell — Unique Product, Revolutionary Procedure
INVOcell® — Unique Product, Revolutionary Procedure * INVO’'s mission ma democratize the fertility industry * IVC provides an alternative to IVF with comparable success rates ADVANCED TREATMENT lul INVOcell (IVC) IVF 8-10%* ~57.1%** ~51.8%** SUCCESS SUCCESS SUCCESS i= * IVC reduces the need for lab
Slide 6: Innovative Commercial Approach
Innovative Commercial Approach Commercialization strategy is focused on: * The development of dedicated “INVO Centers” offering the INVOcell-enabled IVC procedure (with three centers in North America now operational) o p>. L———~—N © positib. bloom fertility INNOVATIVE * The acquisition of existing I
Slide 7: Significant Market Opportunity
Significant Market Opportunity Globally, over 90% of infertile couples remain untreated! * ~15% of reproductive-age women are estimated to be experiencing infertility worldwide! * 96 to 186 million represents the estimated global patient population range with fertility challenges? * Agrowing number
Slide 8: Key Operational Trends to Drive Shareholder Value
4 Key Operational Trends to Drive Shareholder Value 5 * Subject to securing acquisition funding. uly 2023 O INVO center (©2023 INVO Bioscience wiscnsin fertility INSTITUTE IVF Clinic Roll-up Strategy Leading Wisconsin IVF clinic with 5,000+ babies born since 2007 Deal docs signed on March 16, 2023 C
Slide 9: Clinic Operations — INVO Centers
@ Clinic Operations — INVO Centers Strategy to Accelerate IVC Volume and Allow for Share in Total Fertility Cycle Revenue INVO Centers can require less initial investment than traditional IVF clinics and are operationally efficient INVO Centers expected to pass related savings through to patients, i
Slide 10: Clinic Operations — Rapid Growth
@ Clinic Operations — Rapid Growth Representing 75% of revenue in 2022 $25 Clinic Revenue* $2.0 & $15 5 a . NVO $0.5 oe ce nte If fe Begins Within soo Life Beg & 2021 2022 TTM Q1 2023 mINVO Clinics *Revenue includes both consolidated revenue from Atlanta INVO Center, as well as revenue from Birmingh
Slide 11: Clinic Operations — North American Focus
© Clinic Operations — North American Focus Initial list of potential locations is prioritized based on selection factors and growth potential 9 Operating INVO Centers i] Announced Sites 9 Sites under active review* * Cities for which we completed only a preliminary review are not shown on the map. J
Slide 12: Clinic Operations - INVO Centers Are Approaching Breakeven
@ Clinic Operations - INVO Centers Are Approaching Breakeven Q4 2021 Q1 2022 Q2 2022 Q1 2023 uly 2023 Revenue 195,417 311,024 356,361 502,993 516,327 646,707 Opex -1,192,601 -656,032 -745,785 -721,663 -652,394 Net loss -997,184 -345,008 -389,424 -218,672 -136,067 40 Current assets 660,877 696,237 82
Slide 13: Roll-Up Strategy
-Up Strategy @ Roll o oO < @ ‘Os oe 108 ‘o 2023 INVO Bioscie
Slide 14: Roll-Up Strategy — Wisconsin Fertility Institute
@ Roll-Up Strategy — Wisconsin Fertility Institute One of Wisconsin’s leading fertility centers Over 5,000 babies born since 2007, averaging 500+ IVF cycles per annum over the last 5 years Led by Elizabeth Pritts MD, dual certified (REI/OBGYN), internationally recognized physician Services include b
Slide 15: Path to Breakeven
© Path to Breakeven * Cost-saving plan Implemented * Near-term focus on US clinical ops allows for a reduction in certain business development and related medical device costs * Reduced spending on marketing, professional services and R&D costs until INVO reaches break-even run rate * Non-recurring
Slide 16: Expanded INVOcell Use (June 2023)
@ Expanded INVOcell Use (June 2023) * INVOcell now cleared for a 5-day incubation period * Allows for an apples-to-apples comparison between IVC and IVF in marketing campaigns * Data used in support of label expansion demonstrated improved r patient outcomes Tf * Clearance expected to have a positiv
Slide 17: Investment Summary
Investment Summary * Opportunity to address key industry challenges of cost and capacity and, in so doing, accelerate expansion of fertility market Transition: medical device sales to healthcare services * Now participating in total fertility cycle revenue * Strong revenue growth (Q1 up 114% 2023 vs
Slide 18: Financial Summary
Financial Summary @invo bioscience
Slide 19: Revenue Breakdown by Segment
Revenue Breakdown by Segment Reported Clinic All Clinic Revenue INVOcell Product Sales Revenue (Atlanta, Birmingham (Distribution Revenue) (Atlanta Only) and Monterrey) $1,800,000 $1,800,000 $1,686,704 $1,800,000 $1,600,000 $1,600,000 $1,600,000 $1,400,000 $1,400,000 $1,400,000 $1,200,000 $1,200,000
Slide 20: Income Statement Highlights
Income Statement Highlights Product Clinic License Revenue COGS Gross profit Opex Op loss Interest, net Other Net loss EBITDA, adj NOTES FY 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 Q1 2023 544,942 56,750 33,777 58,926 57,889 207,342 50,644 43,745 105,848 112,358 176,395 220,253 614,854 297,381 3
Slide 21: Balance Sheet Highlights
Balance Sheet Highlights 12/31/2021 12/31/2022 3/31/2023 Cash and cash equivalents $5,684,871 $90,135 $2,188,245 Other current assets $620,994 $530,952 $621,517 Lease right of use $2,037,052 $1,808,034 $1,750,175 Investment in joint ventures $1,489,934 $1,237,865 $1,173,577 Total assets $10,466,380
Slide 22: Key Information
Key Information INVO Bioscience (Nasdaq: INVO) Data as of 7/13/2023 Market capitalization $3.3 million Stock price | 52-week range $0.20 | $0. 15 - $1.65 Common shares issued and outstanding 16,837,580 Fully diluted shares outstanding 27,349,416 Management ownership ~3% (~8% including retired founde
Slide 23: Management & Board of Directors
Management & Board of Directors uly 2023 (©2023 INVO Bioscience (O bioscience Sy Sea
Slide 24: Management and Key Personnel
Management and Key Personnel SANOFI GENZYME w® a 9 Steven M. Shum Barbara Levy, MD Chief Executive Officer & Director Senior VP Global Clinical Integration SRRONO EASTSIDE = pi FUKUDA Andrea Goren Inger Britt Carlsson, Ph.D. > Piedmont VW DENSHI ~ Chief Financial Officer VP of Global Medical Affairs
Slide 25: Board of Directors
Board of Directors . (~ Uber Chel gg Chief Executive Officer & Director A — FLO ee @yO ; nCall Eloxx Pharmaceuticals AIBA siaiting solutions x ss Matthew Szot Or: Barbara Ryan Director “; Director JERAPEUTICS Q .... A SRR Uewiibe McKinse’ f_ cw KPMG. & Company [Beam Suntory Radius RIP CURL Director
Slide 26: July 2023
Joly 2023 O |INVOcell Life Begins Within For more information, please Steve Shum, CEO Andrea Goren, CFO 978-878-9505 x506 978-878-9505 x520 sshum@invobio.com agoren@invobio.com (©2023 INVO Bioscience